Living Water DMPK Consulting was founded in 2018 by Dr. Richard Tschirret-Guth.  Dr. Tschirret-Guth obtained a “Diplôme d’Ingénieur Chimiste” in Organic Chemistry from the Ecole Supérior de Chimie Organique et Minérale in Paris and a Ph.D. in Chemistry from UC Santa Barbara, under the supervision of Professor Alison Butler, investigating the function of non-heme vanadium bromoperoxidases.  He then conducted postdoctoral research on hemoproteins structure and function in the laboratories of Professor Paul Ortiz de Montellano at UC San Francisco, followed by research on protein oxidation in ageing and diseases at the NIH in Bethesda, MD.

In 2000, Dr. Tschirret-Guth joined the Department of Drug Metabolism at Merck Research Laboratories in Rahway, NJ where his primary responsibilities as principal investigator and group leader were to provide pre-clinical DMPK support to discovery and development teams. From 2008 to 2010 he led the DMPK group at the Merck Frosst Center for Therapeutic Research before rejoining the DMPK groups in Rahway and Kenilworth, NJ. Over the years, he and his group have contributed to the identification and advancement into early development of over 30 preclinical candidates in a broad range of therapeutic areas (cardiovascular and metabolic diseases, pain, urinary incontinence, infectious diseases, and immunosupressants) which included the NNRTI doravirine, in PhIII development for the treatment of HIV infections, the NK-1 receptor antagonist serlopitant, in PhII development for the treatment of pruritus, and the first orally active glucan synthase inhibitor MK-3118, in PhII development for the treatment of life threatening fungal infections.

Dr. Tschirret-Guth is an author and co-author on 40 peer-reviewed publications and has been an invited speaker at the national meeting of the International Society for the Study of Xenobiotics (ISSX). He has also served as Chair of the ACS North Jersey Drug Metabolism Discussion Group.